Therefore, we have attempted to analyze the immunohistochemical expression of RUNX2 in urinary bladder cancer in this study and to evaluate the significance of its immunoexpression in relation to clinicopathological parameters such as age and gender of patient, tumor size and site, tumor grade, histological subtype, muscle invasion, lymph node metastasis, and pTNM stage. The gene discussed is RUNX2; the disease is urinary bladder cancer.